go back to reference Murray JA, Kelly CP, Green PHR, Marcantonio A, Wu TT, Mäki M, Adelman DC, Ansari S, Ayub K, Basile A, Behrend C, Bercik P, Bressler B, Byrnes V, Chandan VS, Cheekati V, Chipps B, Coates A, Collatrella A, Condemi J, Corder C, Corren J, Curtis C, DeMeo M, Desta T, Devereaux C, DiMarino A, DuPree M, Ennis C, Fedorak R, Fogel R, Freeman S, Freilich B, Friedenberg K, Geenen D, Gill K, Goldsobel A, Goldstein J, Goldstein M, Gordon G, Hardi R, Harris L, Holmes R, Jagarlamundi K, James G, Kaplan M, Kirstein J, Knoll A, Kotfila R, Krause R, Kravitz A, Kreines M, Lähdeaho ML, Lamet M, Laskin K, Lebwohl B, Leffler D, Lewis S, Liakos S, Lundin K, Marks K, Merkes K, Minton S, Moussa S, Narayen V, Nehra V, Newton E, Nyberg A, Oosthuizen J, Otrok T, Patel D, Pepin C, Phillips R, Pyle G, Reichelderfer M, Reid B, Ritter T, Saini S, Sanders D, Schulman M, Semrad C, Shah S, Stockwell D, Strout C, Suez D, Tatum H, Torbenson MS, Turner M, Varunok P, Vazquez-Roque M, Vento A, Welton T, Wohlman R, Wood M, Woods S, Yousef K (2017) No difference between latiglutenase and placebo in reducing villous atrophy or improving symptoms in patients with symptomatic celiac disease. Gastroenterology 152(4):787–798 e2PubMed
Murray JA, Kelly CP, Green PHR, Marcantonio A, Wu TT, Mäki M, Adelman DC, Ansari S, Ayub K, Basile A, Behrend C, Bercik P, Bressler B, Byrnes V, Chandan VS, Cheekati V, Chipps B, Coates A, Collatrella A, Condemi J, Corder C, Corren J, Curtis C, DeMeo M, Desta T, Devereaux C, DiMarino A, DuPree M, Ennis C, Fedorak R, Fogel R, Freeman S, Freilich B, Friedenberg K, Geenen D, Gill K, Goldsobel A, Goldstein J, Goldstein M, Gordon G, Hardi R, Harris L, Holmes R, Jagarlamundi K, James G, Kaplan M, Kirstein J, Knoll A, Kotfila R, Krause R, Kravitz A, Kreines M, Lähdeaho ML, Lamet M, Laskin K, Lebwohl B, Leffler D, Lewis S, Liakos S, Lundin K, Marks K, Merkes K, Minton S, Moussa S, Narayen V, Nehra V, Newton E, Nyberg A, Oosthuizen J, Otrok T, Patel D, Pepin C, Phillips R, Pyle G, Reichelderfer M, Reid B, Ritter T, Saini S, Sanders D, Schulman M, Semrad C, Shah S, Stockwell D, Strout C, Suez D, Tatum H, Torbenson MS, Turner M, Varunok P, Vazquez-Roque M, Vento A, Welton T, Wohlman R, Wood M, Woods S, Yousef K (2017) No difference between latiglutenase and placebo in reducing villous atrophy or improving symptoms in patients with symptomatic celiac disease. Gastroenterology 152(4):787–798 e2
PubMed